Key technical assets of TeraImmune 1) Expansion of human regulatory T cells in vitro 2) Receptors targeting pathological immune cells (T cell/ B cell/ antigen presenting cell) Grant awards 1) SBIR phase 1 (NHLBI, NIH) in April 2018 - grant for small businesses, scientifically verified 2) PACT program (NHLBI, NIH) in November 2018 - service grant supporting overall process development of the cell manufacturing: establishment of standard operating procedure (SOP), QA/QC and regulatory service